These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
57 related items for PubMed ID: 185093
1. Angiotensin antogonists as pharmacological tools. Needleman P, Douglas JR, Jakschik BA, Blumberg AL, Isakson PC, Marshall GR. Fed Proc; 1976 Nov; 35(13):2488-93. PubMed ID: 185093 [Abstract] [Full Text] [Related]
2. Effect of angiotensin-converting enzyme two-week inhibition on renal angiotensin II receptors and renal vascular reactivity in SHR. Haddad G, Garcia R. J Mol Cell Cardiol; 1997 Feb; 29(2):813-22. PubMed ID: 9140837 [Abstract] [Full Text] [Related]
3. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats. De Gennaro Colonna V, Rigamonti A, Fioretti S, Bonomo S, Manfredi B, Ferrario P, Bianchi M, Berti F, Muller EE, Rossoni G. Eur J Pharmacol; 2005 Jun 15; 516(3):253-9. PubMed ID: 15963975 [Abstract] [Full Text] [Related]
4. Mechanism of action of enalapril in experimental hypertension and acute left ventricular failure. Sweet CS, Gaul SL, Reitz PM, Blaine EH, Ribeiro LT. J Hypertens Suppl; 1983 Oct 15; 1(1):53-63. PubMed ID: 6100609 [Abstract] [Full Text] [Related]
5. Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure. Brooks DP, Ruffolo RR. J Hypertens Suppl; 1999 Jun 15; 17(2):S27-32. PubMed ID: 10465064 [Abstract] [Full Text] [Related]
7. Peptides as targets for antihypertensive drug development. Hedner T, Sun X, Junggren IL, Pettersson A, Edvinsson L. J Hypertens Suppl; 1992 Dec 15; 10(7):S121-32. PubMed ID: 1291647 [Abstract] [Full Text] [Related]
8. Effects of atrial natriuretic factor on blood pressure and the renin-angiotensin-aldosterone system. Atlas SA, Volpe M, Sosa RE, Laragh JH, Camargo MJ, Maack T. Fed Proc; 1986 Jun 15; 45(7):2115-21. PubMed ID: 2940120 [Abstract] [Full Text] [Related]
9. Inhibition by bradykinin of the vascular action of angiotensin II in the dog kidney. Susić H, Nasjletti A, Malik KU. J Pharmacol Exp Ther; 1981 Jul 15; 218(1):103-7. PubMed ID: 6165819 [Abstract] [Full Text] [Related]
10. Clinical pharmacology of angiotensin and bradykinin in human forearm vasculature. Ritter JM, Cockcroft JR, Sciberras DG, Goldberg MR. J Hypertens Suppl; 1993 Apr 15; 11(3):S59-61. PubMed ID: 8391072 [Abstract] [Full Text] [Related]
11. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Weir MR. Clin Ther; 2007 Sep 15; 29(9):1803-24. PubMed ID: 18035185 [Abstract] [Full Text] [Related]
12. Chronic salt loading and cardiovascular-associated changes in experimental diabetes in rats. Maeda C, Schaan B, Oliveira E, Oliveira V, De Angelis K, Irigoyen M. Clin Exp Pharmacol Physiol; 2007 Jul 15; 34(7):574-80. PubMed ID: 17581211 [Abstract] [Full Text] [Related]
19. Renin inhibitors, angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists: relationships between blood pressure responses and effects on the renin-angiotensin system. Schalekamp MA, Derkx FH, van den Meiracker AH. J Hypertens Suppl; 1992 Dec 15; 10(7):S157-64. PubMed ID: 1291650 [Abstract] [Full Text] [Related]
20. [Hormonal contribution to short-term variability of blood pressure in a renovascular hypertension model]. Ponchon P, Elghozi JL. Arch Mal Coeur Vaiss; 1995 Aug 15; 88(8):1203-7. PubMed ID: 8572874 [Abstract] [Full Text] [Related] Page: [Next] [New Search]